Publications by authors named "Jason F Lester"

Claim this Profile
C
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Dean A Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Jason F Lester

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.
Alexander M Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L Lim, Takahiro Karasaki, Jason F Lester

Nature· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of lung cancer and impact of subclonal selection in TRACERx.
Alexander M Frankell, Michelle Dietzen, Maise Al Bakir, Emilia L Lim, Takahiro Karasaki, Jason F Lester

Nature· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.
Peter J Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, Rhona McMenemin, Jason F Lester

Radiother Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, Christopher D Brawley, Fiona C Ingleby, Jason F Lester

PLoS One· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Syed A Hussain, Jason F Lester, Richard Jackson, Matthew Gornall, Muneeb Qureshi

Lancet Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Dean A Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G Hanna, Jason F Lester

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations.
Riyaz Shah, Jason F Lester

Clin Lung Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
Peter J Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, Rhona McMenemin, Jason F Lester

JAMA· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: Can either predict completion of treatment?
Jemima T Collins, Simon Noble, Helen E Davies, Daniel Farewell, Jason F Lester

Eur J Cancer Care (Engl)· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
Matthew Q F Hatton, Claire Anne Lawless, Corinne Faivre-Finn, David Landau, Jason F Lester

BMJ Open· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P Hoyle, Jason F Lester

Lancet· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
Jason F Lester, Angela C Casbard, Saly Al-Taei, Richard Harrop, Lajos Katona

Oncoimmunology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Christopher Abbosh, Nicolai J Birkbak, Gareth A Wilson, Mariam Jamal-Hanjani, Tudor Constantin, Jason F Lester

Nature· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study.
Jemima T Collins, Simon Noble, John Chester, Helen E Davies, William D Evans, Jason F Lester

Support Care Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
Toby Talbot, Adam Dangoor, Riyaz Shah, Jay Naik, Denis Talbot, Jason F Lester

Lung Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy.
Rhian Siân Davies, Teresa Perrett, Jane Powell, Jim Barber, Jacob Tanguay, Jason Francis Lester

Med Dosim· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, Jason F Lester

N Engl J Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Mariam Jamal-Hanjani, Gareth A Wilson, Nicholas McGranahan, Nicolai J Birkbak, Thomas B K Watkins, Jason F Lester

N Engl J Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Christopher Abbosh, Nicolai J Birkbak, Gareth A Wilson, Mariam Jamal-Hanjani, Tudor Constantin, Jason F Lester

Nature· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma.
Rhian Siân Davies, Christian Smith, Gwenllian Edwards, Rachel Butler, Diane Parry, Jason Francis Lester

Lung Cancer Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostaglandin E-mediated adenosinergic effects on CD14 cells: Self-amplifying immunosuppression in cancer.
Saly Al-Taei, Josephine Salimu, Lisa K Spary, Aled Clayton, Jason F Lester

Oncoimmunology· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
Rhian Siân Davies, Daniel John Nelmes, Rachel Butler, Jason Francis Lester

Anticancer Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Rhian Siân Davies, Christian Smith, Jason Francis Lester

Anticancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
Rhian Siân Davies, Christian Smith, Michael Robert Button, Jacob Tanguay, Jim Barber, Jason Francis Lester

Anticancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis